by Intramuscular vaccine adjuvants are primarily used in vaccines to enhance the immune response and provide longer lasting protection against various infectious diseases and disorders. They function by stimulating the innate immune system and have the potential to achieve higher antibody titers, cellular immune responses, cross-protection, and longer-lasting immunity using smaller doses of antigens.
The global Intramuscular Vaccine Adjuvants Market is estimated to be valued at US$ 694.19 Mn or Mn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends in the intramuscular vaccine adjuvants market is the increasing adoption of oil-in-water adjuvants. Oil-in-water adjuvants play a major role in enhancing the immunogenicity of subunit vaccines by forming a depot at the injection site, which allows a slow release of antigen over a prolonged period of time. For instance, MF59 adjuvant developed by Novartis is an oil-in-water adjuvant approved for use in influenza vaccines in Europe and Latin America. Its efficacy and safety has been demonstrated in clinical trials thereby increasing its adoption in intramuscular vaccines.
SWOT Analysis
Strength: Intramuscular vaccine adjuvants help boost immune response and long-lasting immunity against infectious diseases. They allow for smaller doses of antigen and elicit strong immune responses.
Weakness: Adjuvants can cause side effects like pain, swelling, and redness at the injection site. Their safety profile is still being evaluated for long-term effects.
Opportunity: Growing focus on pandemic preparedness and development of vaccines for infectious diseases like COVID-19 presents major opportunities. Increasing R&D investments in immunology also support growth.
Threats: Stringent regulations around adjuvant safety testing may delay new product approvals. Alternative vaccine delivery methods can reduce the need for potent adjuvants over time.
Key Takeaways
The Global Intramuscular Vaccine Adjuvants Market Size is expected to witness high growth, exhibiting CAGR of 6.7% over the forecast period, due to increasing demand for adjuvanted vaccines across major diseases.
Market size: The intramuscular vaccine adjuvants market size for 2023 is estimated to be US$ 694.19 Mn. Growth in pandemic preparedness programs and increasing healthcare budgets are fueling the market expansion.
Regional analysis: North America dominated the global market in 2022 due to focus on vaccine R&D. Asia Pacific is anticipated to exhibit fastest growth over the forecast period supported by rising immunization in developing nations like India and China.
Key players: Key players operating in the intramuscular vaccine adjuvants market are Novavax, Inc., Adjuvance Technologies, Inc., Invivogen, Vaxine Pty Ltd., SEPPIC, SPI Pharma, Inc., Agenus Inc., Avanti Polar Lipids, Inc., CSL Limited, and OZ Biosciences. Major players are collaborating with drug makers and researchers to developadjuvanted preventive therapies.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
